DOI: 10.12890/2020_001943

COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use

Authors

  • Jiali Fang Department of Medicine, University of Illinois at Chicago, Chicago, USA
  • Matthew Genco Department of Medicine, University of Illinois at Chicago, Chicago, USA
  • Rachel Caskey Department of Medicine, University of Illinois at Chicago, Chicago, USA

jfang23@uic.edu

Abstract

Objective: To describe a patient who developed euglycaemic diabetic ketoacidosis (DKA) in the setting of SGLT2 inhibitor use precipitated by COVID-19.
Patient and methods: A 52-year-old male with type II diabetes on empagliflozin and no history of DKA presented with symptoms of COVID-19 as well as laboratory findings consistent with euglycaemic DKA. His hospital course was complicated by recurrent episodes of euglycaemic DKA as well as hyperglycaemic DKA. 
Conclusion: SGLT2 inhibitors should be held as early as possible in COVID-19 cases due to the risk of euglycaemic DKA. These patients should also have more intense glucose monitoring.

View the entire article

Downloads

References

  1. Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 2016;38(12):2654–2664.e1.
  2. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8(6):546–550.
  3. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020;22:1935–1941.
  4. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014;53(3):213–225.
  5. Fernandez-Fernandez B, D’Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, et al. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19. J Clin Med 2020;9(7):2030.

Published

2020-10-26

Issue

Vol. 7 No. 11 (2020)

Categories

How to Cite

1.
Fang J, Genco M, Caskey R. COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use. EJCRIM [Internet]. 2020 Oct. 26 [cited 2026 Nov. 3];7(11). Available from: https://ejcrim.com/index.php/ejcrim/article/view/1943